BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion [Yahoo! Finance]
BioAge Labs, Inc. (BIOA)
Last bioage labs, inc. earnings: 8/3 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
investor.bio-amber.com
Company Research
Source: Yahoo! Finance
in Phase 1 with 24-hour IC90 coverage at 60 mg, ~93% IL-1ß suppression, and pronounced biomarker changes including ~86% reduction in hs-CRP and ~50% reduction in IL-6 in obese participants with elevated inflammation. BioAge will release the full Phase 1 dataset in H1 and plans a ~3-month, placebo-controlled cardiovascular study (~50 patients on drug vs. 50 placebo) in H2 using CRP as the primary endpoint to inform dose selection and cardiovascular biomarker effects. The company is also expanding into retinal disease, planning a mid-year diabetic macular edema (DME) proof-of-concept trial with a three-arm design (VEGF±BGE-102 and sham+BGE-102), supported by preclinical data showing oral BGE-102 improves retinal vascular permeability and microvascular integrity. Interested in BioAge Labs, Inc.? Here are five stocks we like better. BioAge Labs (NASDAQ:BIOA) outlined its strategy and near-term clinical plans at Oppenheimer's 36th Annual Life Science Conference, emphasizing its foc
Show less
Read more
Impact Snapshot
Event Time:
BIOA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIOA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIOA alerts
High impacting BioAge Labs, Inc. news events
Weekly update
A roundup of the hottest topics
BIOA
News
- BioAge Labs (BIOA) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $60.00 price target on the stock.MarketBeat
- BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
- BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswire
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CETPR Newswire
- Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CETPR Newswire
BIOA
Earnings
- 11/6/25 - Beat
BIOA
Sec Filings
- 2/19/26 - Form 4
- 2/19/26 - Form 4
- 2/19/26 - Form 4
- BIOA's page on the SEC website